We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of...
FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...
FOSTER CITY, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
false 0001831363 0001831363 2024-02-06 2024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 1.49700598802 | 6.68 | 6.94 | 6.14 | 612285 | 6.37073238 | CS |
4 | -0.84 | -11.0236220472 | 7.62 | 8.68 | 5.74 | 1165519 | 7.27968099 | CS |
12 | 0.39 | 6.10328638498 | 6.39 | 8.68 | 4.825 | 841646 | 6.85630975 | CS |
26 | 1.85 | 37.5253549696 | 4.93 | 8.68 | 3.26 | 657163 | 6.28063488 | CS |
52 | -3.25 | -32.4027916251 | 10.03 | 14.0435 | 3.26 | 680203 | 7.69544079 | CS |
156 | -13.36 | -66.3356504469 | 20.14 | 22.45 | 1.45 | 340209 | 7.44829761 | CS |
260 | -10.17 | -60 | 16.95 | 28.36 | 1.45 | 336491 | 7.94749101 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions